In-keeping with our findings, an open-label study of 26 men with PCa showed that short-term (6 weeks on average) supplementation with EGCG (800 mg daily) resulted in a reduction in IGF-I serum level (SD) by 28 ng/ml (57.2), IGFBP-3 by 291 ng/ml (606) and IGF-I: IGFBP-3 ratio by 0.0029 (0.0123) (McLarty et al., 2009). The gene discussed is IGF1; the disease is posterior cortical atrophy.